Phase I/II of a CpG-Activated Whole Cell Vaccine Followed by Autologous Immunotransplant for MCL

This study is currently recruiting participants. (see Contacts and Locations)
Verified May 2015 by Stanford University
National Institutes of Health (NIH)
Information provided by (Responsible Party):
Ronald Levy, Stanford University Identifier:
First received: June 20, 2007
Last updated: May 19, 2015
Last verified: May 2015
Mantle Cell Lymphoma is a sub-type of Non-Hodgkin's Lymphoma which is generally considered incurable with current therapy. Our goal is to accrue 59 patients who receive an autologous vaccine against their individual lymphoma after undergoing stem cell transplantation. Our hope is that vaccination will prolong the time which patients will stay in remission from their disease.

Condition Intervention Phase
Lymphoma, Mantle-Cell
Biological: CpG-MCL vaccine, primed T-cells
Procedure: Autologous peripheral blood stem cell transplantation
Procedure: CT scan
Procedure: PET-CT scan
Drug: PF-3512676
Drug: Rituximab
Phase 2

Study Type: Interventional
Study Design: Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Phase I/II Study of a CpG-Activated Whole Cell Vaccine Followed by Autologous "Immunotransplant" for Mantle Cell Lymphoma

Resource links provided by NLM:

Further study details as provided by Stanford University:

Primary Outcome Measures:
  • The primary endpoint of the trial is freedom from molecular residual disease (MRD) at the landmark of one-year post-transplant. [ Time Frame: Samples for MRD analysis are collected every 3 months until one-year post transplant. ] [ Designated as safety issue: No ]
    After the one-year mark, samples for MRD analysis will be collected every 6 months for 3 years or until disease progression.

Secondary Outcome Measures:
  • Secondary objectives are Time To Clinical Progression (TTP), and evaluation of anti-tumor immune responses after vaccination, and after immunotransplant. progression-free survival. [ Time Frame: 1 year, 3 years, 5 years ] [ Designated as safety issue: No ]

Estimated Enrollment: 59
Study Start Date: August 2009
Estimated Study Completion Date: September 2020
Estimated Primary Completion Date: September 2017 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: "CpG-MCL" vaccine
Patients will initially receive three 'priming' CpG-MCL vaccinations in 21 days at 4-7 day intervals, followed by collection of "primed" T-Cells. Subsequently, within 72 hours of autologous hematopoetic cell transplant (AHCT)(standard of care procedure), the patient will receive his/her CpG-MCL vaccine and reinfusion of primed T cells ("immunotransplant"). At >/= 3 months after AHCT, when medically feasible, the patient will receive the final CpG-MCL vaccine. Regular follow-up research analysis of molecular residual disease will continue for 3 years or until disease progression.
Biological: CpG-MCL vaccine, primed T-cells
Other Name: CpG-activated, autologous tumor vaccine
Procedure: Autologous peripheral blood stem cell transplantation
Standard of Care
Other Name: Hematopoietic stem cell transplantation
Procedure: CT scan
Standard of Care
Other Name: X-ray computed tomography
Procedure: PET-CT scan
Standard of Care
Other Name: Poset emission tomography
Drug: PF-3512676
18 mg subcutaneous injection
Other Name: Pfizer
Drug: Rituximab
375 mg/m2 iv Standard of care.
Other Names:
  • Rituxan
  • MabThera


Ages Eligible for Study:   18 Years to 70 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Patients must be newly diagnosed with MCL, have an accessible disease site for excisional biopsy or sufficient peripheral blood tumor burden to safely leukapherese.
  • By standard clinical criteria be medically appropriate to receive induction chemotherapy and high-dose chemotherapy with AHCT.
  • Must be between 18 to 70 years of age.
  • Serum creatinine <2.0 or 24-hour creatinine clearance >60 ml/min.
  • Patients must be HIV negative.
  • ECOG performance status 0, 1, or 2.
  • Patients must be capable of signing an informed consent.

Exclusion Criteria:

  • Patients who are currently taking immunosuppressive medications.
  • Severe psychological or medical illness.
  • Patients may not be receiving any other investigational agents.
  • Pregnant or lactating women.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00490529

United States, California
Stanford University Medical Center Recruiting
Stanford, California, United States, 94305
Contact: Ami Okada    650-725-4968   
Sub-Investigator: Holbrook Kohrt, MD, PhD         
Sub-Investigator: Ranjana Advani, MD         
Sub-Investigator: Robert Negrin, MD         
Sub-Investigator: David Miklos, MD, PhD         
Sub-Investigator: Wen Kai Weng, MD, PhD         
Sub-Investigator: Sally Arai, MD, PhD         
Sub-Investigator: Lauren Maeda, MD         
Sponsors and Collaborators
Ronald Levy
National Institutes of Health (NIH)
Principal Investigator: Ronald Levy Stanford University
  More Information

Responsible Party: Ronald Levy, Professor, Stanford University Identifier: NCT00490529     History of Changes
Other Study ID Numbers: LYMNHL0040-BMT212  96940  LYMNHL0040-BMT212  5089 
Study First Received: June 20, 2007
Last Updated: May 19, 2015
Health Authority: United States: Institutional Review Board
United States: Food and Drug Administration

Additional relevant MeSH terms:
Lymphoma, Mantle-Cell
Immune System Diseases
Immunoproliferative Disorders
Lymphatic Diseases
Lymphoma, Non-Hodgkin
Lymphoproliferative Disorders
Neoplasms by Histologic Type processed this record on February 04, 2016